These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 28277622

  • 1. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
    Zheng N, Chen J, Li T, Liu W, Liu J, Chen H, Wang J, Jia L.
    Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622
    [Abstract] [Full Text] [Related]

  • 2. Mifepristone inhibits ovarian cancer metastasis by intervening in SDF-1/CXCR4 chemokine axis.
    Zheng N, Chen J, Liu W, Liu J, Li T, Chen H, Wang J, Jia L.
    Oncotarget; 2017 Aug 29; 8(35):59123-59135. PubMed ID: 28938623
    [Abstract] [Full Text] [Related]

  • 3. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
    Zheng N, Liu W, Chen J, Li B, Liu J, Wang J, Gao Y, Shao J, Jia L.
    Mol Carcinog; 2019 Jan 29; 58(1):144-155. PubMed ID: 30259564
    [Abstract] [Full Text] [Related]

  • 4. [Relationship between chemokine axis CXCL12-CXCR4 and epithelial ovarian cancer].
    Guo Q, Wu XH, Lü YP, Yang B, Xu F, Zhang SJ.
    Zhonghua Yi Xue Za Zhi; 2013 Jun 04; 93(21):1677-80. PubMed ID: 24125682
    [Abstract] [Full Text] [Related]

  • 5. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
    Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F.
    Int J Cancer; 2008 Jan 01; 122(1):91-9. PubMed ID: 17893878
    [Abstract] [Full Text] [Related]

  • 6. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
    Liu Y, Ren CC, Yang L, Xu YM, Chen YN.
    J Cell Physiol; 2019 Apr 01; 234(4):3897-3909. PubMed ID: 30191987
    [Abstract] [Full Text] [Related]

  • 7. Metapristone (RU486 derivative) inhibits cell proliferation and migration as melanoma metastatic chemopreventive agent.
    Zheng N, Chen J, Liu W, Wang J, Liu J, Jia L.
    Biomed Pharmacother; 2017 Jun 01; 90():339-349. PubMed ID: 28376402
    [Abstract] [Full Text] [Related]

  • 8. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N, Liu W, Li B, Nie H, Liu J, Cheng Y, Wang J, Dong H, Jia L.
    J Exp Clin Cancer Res; 2019 May 31; 38(1):232. PubMed ID: 31151472
    [Abstract] [Full Text] [Related]

  • 9. Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin to realize cancer metastasis chemoprevention.
    Yu S, Yan C, Yang X, He S, Liu J, Qin C, Huang C, Lu Y, Tian Z, Jia L.
    Sci Rep; 2016 Mar 02; 6():22388. PubMed ID: 26932781
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo efficacy and safety evaluation of metapristone and mifepristone as cancer metastatic chemopreventive agents.
    Wang J, Chen J, Zhu Y, Zheng N, Liu J, Xiao Y, Lu Y, Dong H, Xie J, Yu S, Shao J, Jia L.
    Biomed Pharmacother; 2016 Mar 02; 78():291-300. PubMed ID: 26898454
    [Abstract] [Full Text] [Related]

  • 11. CXCL12-CXCR4 Axis Promotes Proliferation, Migration, Invasion, and Metastasis of Ovarian Cancer.
    Guo Q, Gao BL, Zhang XJ, Liu GC, Xu F, Fan QY, Zhang SJ, Yang B, Wu XH.
    Oncol Res; 2014 Mar 02; 22(5-6):247-58. PubMed ID: 26629936
    [Abstract] [Full Text] [Related]

  • 12. Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway.
    Zheng G, Shen Z, Chen H, Liu J, Jiang K, Fan L, Jia L, Shao J.
    Biomed Pharmacother; 2017 Jun 02; 90():437-445. PubMed ID: 28391165
    [Abstract] [Full Text] [Related]

  • 13. [Effect of chemokine CXCL12 and its receptor CXCR4 on proliferation, migration and invasion of epithelial ovarian cancer cells].
    Jiang YP, Wu XH, Xing HY, DU XY.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jun 02; 42(6):403-7. PubMed ID: 17697603
    [Abstract] [Full Text] [Related]

  • 14. Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion.
    Miyanishi N, Suzuki Y, Simizu S, Kuwabara Y, Banno K, Umezawa K.
    Biochem Biophys Res Commun; 2010 Dec 03; 403(1):154-9. PubMed ID: 21059341
    [Abstract] [Full Text] [Related]

  • 15. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.
    Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G, Balkwill FR.
    Cancer Res; 2002 Oct 15; 62(20):5930-8. PubMed ID: 12384559
    [Abstract] [Full Text] [Related]

  • 16. Role of CXCL12 in metastasis of human ovarian cancer.
    Jiang YP, Wu XH, Xing HY, DU XY.
    Chin Med J (Engl); 2007 Jul 20; 120(14):1251-5. PubMed ID: 17697577
    [Abstract] [Full Text] [Related]

  • 17. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
    Salomonnson E, Stacer AC, Ehrlich A, Luker KE, Luker GD.
    PLoS One; 2013 Jul 20; 8(1):e51500. PubMed ID: 23372646
    [Abstract] [Full Text] [Related]

  • 18. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer.
    Wu W, Yu LH, Ma B, Xu MJ.
    PLoS One; 2014 Jul 20; 9(3):e89841. PubMed ID: 24598933
    [Abstract] [Full Text] [Related]

  • 19. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
    Xue J, Li R, Gao D, Chen F, Xie H.
    Int J Nanomedicine; 2020 Jul 20; 15():5701-5718. PubMed ID: 32848392
    [Abstract] [Full Text] [Related]

  • 20. Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer.
    Ma L, Qiao H, He C, Yang Q, Cheung CH, Kanwar JR, Sun X.
    Invest New Drugs; 2012 Apr 20; 30(2):508-17. PubMed ID: 21080209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.